Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
1.889
-0.042 (-2.15%)
Nov 20, 2024, 4:00 PM EST - Market closed
Immuron Revenue
In the fiscal year ending June 30, 2024, Immuron had annual revenue of 4.90M AUD with 171.67% growth. Immuron had revenue of 2.55M in the half year ending June 30, 2024, with 376.82% growth.
Revenue (ttm)
4.90M AUD
Revenue Growth
+171.67%
P/S Ratio
n/a
Revenue / Employee
700,409 AUD
Employees
7
Market Cap
11.21M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 4.90M | 3.10M | 171.67% |
| Jun 30, 2023 | 1.80M | 1.04M | 135.85% |
| Jun 30, 2022 | 765.19K | 619.42K | 424.91% |
| Jun 30, 2021 | 145.78K | -2.37M | -94.21% |
| Jun 30, 2020 | 2.52M | 131.14K | 5.49% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| China Jo-Jo Drugstores | 154.54M |
| Streamline Health Solutions | 20.30M |
| ImmunoPrecise Antibodies | 17.44M |
| MSP Recovery | 10.73M |
| Aspira Women's Health | 8.96M |
| PAVmed | 4.03M |
| Lyra Therapeutics | 1.47M |
IMRN News
- 3 days ago - Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event - Accesswire
- 5 weeks ago - Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Immuron Travelan® continued strong sales growth - GlobeNewsWire
- 6 weeks ago - NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - GlobeNewsWire
- 2 months ago - Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma - GlobeNewsWire
- 2 months ago - Immuron Plans Phase 2 Trial for IMM-529 following FDA review - GlobeNewsWire
- 3 months ago - Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now - GlobeNewsWire
- 3 months ago - Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan® - GlobeNewsWire